^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1 underexpression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
7d
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Keytruda (pembrolizumab) • WM-A1-3389
7d
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer. (PubMed, J Extracell Vesicles)
Patients with high baseline levels of PD-L1+ lEVs in blood showed a significantly better response to immunotherapy and prolonged survival. This was particularly true in the subgroup of NSCLC patients with low or absent tPD-L1 expression, thus identifying PD-L1-positive lEVs in plasma as a novel predictive and prognostic marker for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SELP (Selectin P)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
10d
Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients. (PubMed, Thorac Cancer)
PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.
Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • PD-L1 overexpression • KRAS G12C • ALK positive • PD-L1 underexpression • PD-L1 negative • KRAS G12 • EGFR positive • KRAS G12C + PD-L1 expression • PD-L1-L
17d
An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer. (PubMed, Front Immunol)
Patients with low expression of PDL1 or high expression of CTLA4 and low ERLS exhibited significantly better survival prospects, whereas patients with high ERLS and low levels of PDL1 or CTLA4 exhibited the poorest outcomes. Our study constructed an ERLS model that can predict prognostic risk and immunotherapy response, optimizing clinical management for OC patients.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Machine learning
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • TMB-H • PD-L1 overexpression • PD-L1 underexpression • CTLA4 expression
30d
Programmed Death-Ligand 1 (PD-L1) Expression in Penile Squamous Cell Carcinoma - A Comparative Assessment of the Reference Clone 22C3 with SP263 and E1L3N Clones along with a Correlation of Clinicopathologic and Survival Parameters (USCAP 2024)
1. Ours is the first study to demonstrate that SP263 and E3L1N can reliably be used to evaluate PD-L1 in PCs as there is good concordance with the reference clone 22C3. 2.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1 negative • CDKN2A negative • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
2ms
Integrative analysis of the cuproptosis-related gene ATP7B in the prognosis and immune infiltration of IDH1 wild-type glioma. (PubMed, Gene)
In conclusion, our research constructed a prognostic cuproptosis-related gene signature model to predict the prognosis of IDH1 wild-type glioma. ATP7B is deemed to be a potential prognostic indicator and novel immunotherapy biomarker for IDH1 wild-type glioma patients.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD8 (cluster of differentiation 8)
|
PD-L1 overexpression • PD-L1 underexpression • IDH wild-type
2ms
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. (PubMed, NPJ Breast Cancer)
In addition, patients with B7-H3 high and PD-L1 low expression showed the lowest anti-tumor immune infiltration, the highest collagen level, and the lowest therapeutic responses to multiple therapies, which mostly belong to armored-cold tumors. Overall, this research provides a novel subtyping strategy based on the combination of B7-H3/PD-L1 expression, which leads to a novel approach for the management of TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
|
PD-L1 expression • PD-L1 underexpression • CD276 expression • PD-L1-L
2ms
Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow. (PubMed, J Immunother Cancer)
ICI-based regimens are not associated with a survival benefit versus chemotherapy in subgroups of advanced/metastatic TNBC that express low PD-L1 levels.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Keytruda (pembrolizumab)
2ms
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy. (PubMed, Pharmacoeconomics)
The use of WGS-TMB is not cost effective compared to PD-L1 for immunotherapy treatment selection in non-squamous metastatic non-small cell lung cancer in the Netherlands. WGS-TMB could become cost effective provided there is a reduction in the cost of WGS testing or there is an increase in the predictive value of WGS-TMB for immunotherapy effectiveness. Alternatively, a combination strategy of PD-L1 testing with WGS-TMB would be cost effective if used to support the choice to withhold immunotherapy in patients with a low expected benefit of immunotherapy.
Journal • HEOR • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness • Cost effectiveness • Metastases
|
TMB (Tumor Mutational Burden)
|
TMB-H • PD-L1 underexpression • TMB-L • PD-L1-L
2ms
Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma. (PubMed, J Reprod Immunol)
The frequent infiltration of CD45RO, along with variable expression of PD-1 and PD-L1 on TILs and tumor cells, could impact the effectiveness of anti-tumor responses and immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 overexpression • PD-L1 underexpression • PD-1 expression
3ms
The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. (PubMed, Turk J Biol)
The activation of angiogenesis and metastasis-related pathways by anti-PD-L1 treatment in PD-L1 high tumors might be a tumor-promoting mechanism. The decrease of VEGFA, TGFβ1 and EGFR upon anti-PD-L1 treatment in PD-L1 low tumor cells provides a rationale for the use of those antibodies in PD-L1 low tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • PD-L1 overexpression • EGFR expression • PD-L1 underexpression • CDH1 expression • VEGFA expression • PD-L1-L
3ms
TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma. (PubMed, Am J Physiol Cell Physiol)
Additionally, in vivo experiments further verified that TLR9 promoted tumour growth and immune escape by inhibiting PARP1. Collectively, TLR9 activation induced immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in OSCC, providing important insights for subsequent in-depth exploration of the mechanism of OSCC.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TLR9 (Toll Like Receptor 9)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • TLR9 expression
4ms
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
4ms
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • PD-L1 underexpression • PD-L1 negative
4ms
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
4ms
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
4ms
Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model. (PubMed, Radiother Oncol)
The combination of local RT and an anti-GITR agonist significantly enhanced the anti-tumor immune responses induced by PD-L1 blockade. These results provide the preclinical rationale for the combination of therapy.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF18 (TNF Receptor Superfamily Member 18)
|
PD-L1 underexpression
5ms
Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer (SABCS 2023)
The recent approvals and data of pembrolizumab (anti-PD-1 inhibitor) in combination with chemotherapy in advanced-metastatic and early high-risk TNBC, and sacituzumab govitecan (an ADC that targets the tumor cell surface antigen TROP2 coupled with the irinotecan metabolite SN-38) in metastatic TNBC, has shed light on some of the immune and cancer signaling associated with TNBC. This preliminary analysis confirmed that only a limited number of early TNBC highly expressed PD-L1 and that a different immune suppressive landscape for PD-L1± and TROP2± tumors exists. In addition, our data suggest that early TNBC cases lacking PD-L1 might escape immune surveillance by virtue of the upregulation of key alternate signaling. Ongoing efforts investigating the expression of such markers on stroma/epithelial tumor components will help to clarify their biological, clinical, and potential therapeutic role in TNBC.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • IFNG (Interferon, gamma) • MUC1 (Mucin 1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • PD-L1 overexpression • HER-2 expression • PD-L1 underexpression • TROP2 expression • VTCN1 underexpression • TROP2 positive • VTCN1 expression • PD-L1-L
|
Keytruda (pembrolizumab) • irinotecan • Trodelvy (sacituzumab govitecan-hziy)
5ms
Identifying new immune-related biomarkers in TNBC with a look at PD-L1 cell-autonomous role. (SABCS 2023)
To further demonstrate the role of PD-L1, we treated the PDL1-high expression cells MDA-MB-231, PD-L1 silenced MDA-MB-231 clones, and PD-L1 low expression cells MCF-7 with Durvalumab, an anti-PD-L1...Here, we further characterized the cellular autonomic role of PD-L1 in breast cancer and showed a differential role of basal PD-L1 expression in PD-L1 checkpoint inhibitors treatment efficacy. This suggests a potential role in monitoring PD-L1 expression indirect biomarkers (i.e. miR-320a, miR-145 and CD73) during ICIs treatment.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NT5E (5'-Nucleotidase Ecto) • MIR320A (MicroRNA 320a) • MIR145 (MicroRNA 145) • MIR30E (MicroRNA 30e)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1 negative • CD73 expression • PD-1-L • PD-L1-L
|
Imfinzi (durvalumab)
5ms
Novel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling (SABCS 2023)
We present novel metrics of HER2 heterogeneity via HDmIF, which offer detailed characterization of the diversity of HER2 expression in a large, clinically-annotated cohort with long-term follow-up. Identification of a strong association between immunophenotype and RFS supports further investigation of the highly immune activated subsets of ER-/HER2+ breast cancer. Strong correspondence of HER2 IF and IHC and our HAIQu methodology offers a pathway to translation of HER2het metrics to clinical practice.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 positive • HER-2 expression • PD-L1 underexpression • HR negative • ERBB3 expression • PD-1-L • PD-L1-L
5ms
Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study (SABCS 2023)
BEGONIA is an ongoing Simon 2-stage, multicenter, multi-arm platform study evaluating the safety and efficacy of durvalumab (D), an anti–PD-L1 monoclonal antibody, with or without paclitaxel, in combination with novel oncology therapies as first-line treatment for a/mTNBC (NCT03742102). TROP2 expression will be assessed by IHC. Enrollment is ongoing.
P1/2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • PD-L1 underexpression • TROP2 expression • PD-L1-L
|
VENTANA PD-L1 (SP263) Assay
|
Imfinzi (durvalumab) • paclitaxel • datopotamab deruxtecan (DS-1062a)
5ms
Classic Hodgkin Lymphomas Display Neuronal-Glial Lineage Transdifferentiation (ASH 2023)
1N). Altogether, these single-cell multi-omics studies indicated that an epigenetically encoded NG program may cooperate with lymphoma driving mutations to drive the development of HL, paving novel avenues of therapy.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL2 (Chemokine (C-C motif) ligand 2) • CD79A (CD79a Molecule) • SOCS1 (Suppressor Of Cytokine Signaling 1) • CCL22 (C-C Motif Chemokine Ligand 22) • H1-4 (H1.4 Linker Histone, Cluster Member) • NRG2 (Neuregulin 2) • RACK1 (Receptor For Activated C Kinase 1)
|
PD-L1 underexpression • CD19 expression
5ms
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (KEYNOTE-E90) (clinicaltrials.gov)
P1, N=54, Not yet recruiting, Wellmarker Bio | Trial completion date: Sep 2025 --> Feb 2026 | Initiation date: Aug 2023 --> Jan 2024 | Trial primary completion date: Sep 2025 --> Feb 2026
Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Keytruda (pembrolizumab) • WM-A1-3389
5ms
Development and Preclinical Evaluation of [Ga]BMSH as a New Potent Positron Emission Tomography Tracer for Imaging Programmed Death-Ligand 1 Expression. (PubMed, Pharmaceuticals (Basel))
Micro-PET/CT imaging of tumor-bearing mice further confirmed that, compared to [F]FDG, [Ga]BMSH can specifically identify tumors with varying levels of PD-L1 expression. Our findings suggest that the [Ga]BMSH is a PD-L1 radioligand with ideal imaging properties, and its further application in the clinical screening of PD-L1 overexpressing tumors may improve ORR for immunotherapy.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1-L
5ms
PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. (PubMed, Cancers (Basel))
Conventional PD-L1 IHC testing has inherent limitations, making it an imperfect reference standard for evaluating novel testing technologies. RNA-seq offers an objective PD-L1 measure that could represent a complementary method to IHC to improve NSCLC patient selection for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker • Discordant
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1 negative
|
Keytruda (pembrolizumab)
6ms
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer (DGHO 2023)
Our data have identified PD-L1 + lEVs as a novel predictive and prognostic marker for immunotherapy in NSCLC that is superior to the standard-of-care measurement of tissue PD-L1 in selecting responders for immunotherapy.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SELP (Selectin P)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
6ms
Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients. (PubMed, Am J Transl Res)
The expression of PD-L1 and Ki-67 is related to some clinicopathologic features and inflammatory factors, which brings new sight for exploiting combination biomarkers and therapeutic strategies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression
7ms
Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor. (PubMed, Asian Pac J Cancer Prev)
PD-L1 expression assessment in HL patients is a valuable tool for prediction of the disease subtype, progression, stage, and treatment outcome. IHC method as an available, simple, rather cheap, and efficient tool could use for evaluation of PD-L1 expression and predicting the prognosis of HL disease, elsewhere.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1)
|
PD-L1 overexpression • PD-L1 underexpression
7ms
Prostate cancer cells synergistically defend against CD8 T cells by secreting exosomal PD-L1. (PubMed, Cancer Med)
In summary, tumor cells share PD-L1 synergistically against T cells through exosomes. Inhibition of exosome secretion or prevention of PD-L1 sorting into exosomes may improve the therapeutic response of prostate tumors to anti-PD-L1 therapy.
Journal
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
7ms
Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters: A study of 134 patients. (PubMed, Am J Clin Pathol)
Overall, PD-L1 expression is associated with high-grade and metastatic tumors. Lower PD-L1 expression is observed more frequently in HPV-associated (warty or basaloid) subtypes than in other, predominantly HPV-independent types. As a result, PD-L1 positivity, including higher expression, portends lower overall and cancer-specific survival. These data provide a rational for further investigating PD-L1-based immunotherapeutics in PC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1 negative • CDKN2A negative • PD-L1-L
8ms
AN UNSUAL AND MASQUERADING CASE OF METASTATIC OR MULTIFOCAL PULMONARY ADENOCARCINOMA: CASE OF LOOKING BEYOND THE APPARENT (CHEST 2023)
We demonstrate a case of rapidly progressing multiple bilateral pulmonary nodules in short interval of 3 months that turned out to be lung adenocarcinoma.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression
8ms
Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma (ESMO 2023)
Interestingly, the nucleic size and shape of tumor cell, lymphocyte, stroma cell, and macrophage were all dramatically smaller than CD3CD4 score=0 group. Conclusions Our results implicated stage II-III LCNEC with high CD3+ and CD4+ cell infiltration could benefit from aCT and PD-L1 blockade, highlighting the potential role of rare tumor microenvironment cellular morphological characteristics in chemo-immunotherapy sensitivity and surgery prognosis.
Clinical • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
8ms
PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis (ESMO 2023)
Likewise, patients with PD-L1 high expressing tumors were at a higher risk of tumor progression, although this was not significant (PD-L1-high [n=513] vs PD-L1-low [n=436], HR=1.076, 95%-CI: 0.923 - 1.253, p=0.35). Conclusions Our study found PD-L1 expression is a negative predictor of overall survival in aESCC treated with first-line chemotherapy.
PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1-L
8ms
P1/2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • PD-L1 underexpression • TROP2 expression • PD-L1-L
|
VENTANA PD-L1 (SP263) Assay
|
Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a)
8ms
Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study (IASLC-WCLC 2023)
Data from the RELEVANCE study found longer median OS, rwPFS, and TTNT in patients who received CRT+durvalumab than CRT alone and no new safety signals were identified. These real-world Canadian data support the efficacy and safety of CRT+durvalumab in patients with unresectable stage III NSCLC identified in the PACIFIC trial.
Clinical • Real-world evidence • Real-world
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1 negative • ALK mutation • PD-L1-L
|
Imfinzi (durvalumab)
8ms
Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center (IASLC-WCLC 2023)
Introduction: KRAS is the most common oncogenic driver of non-small cell lung cancer, and in the past year, 2 agents, sotorasib and adagrasib, have been approved by the FDA for treatment of advanced KRAS G12C NSCLC. We identified 61 patients with KRAS G12C NSCLC over seven years. 14.7% of patients were Black, and among patients with stage IV disease, 13.5% were Black. Black and White patients were similar in age and smoking status, and prior work from our group shows no difference in medical comorbidities.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • PD-L1 underexpression • PD-L1 negative • KRAS G12 • PD-1-L • PD-L1-L
|
Lumakras (sotorasib) • Krazati (adagrasib)
8ms
EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells. (PubMed, Cell Mol Biol Lett)
EFEMP2 could bind to EGFR to activate ERK1/2/c-Jun pathway and regulate PD-L1 expression, furthermore PD-L1 was extremely essential for EFEMP2 to promote ovarian cancer cells invasion and dissemination in vitro and in vivo. Targeted therapy against the source gene EFEMP2 is our future research direction, which may better inhibit the invasion and metastasis of ovarian cancer cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
ECM2 (Extracellular Matrix Protein 2) • JUN (Jun proto-oncogene)
|
PD-L1 expression • PD-L1 underexpression
|
Mekinist (trametinib) • Gilotrif (afatinib)
9ms
PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients. (PubMed, J Hepatocell Carcinoma)
Evaluation of IDO and PD-L1 expression may add therapeutic advantage in non-HCV and non-HBV-associated HCC patients that overexpress IDO. Further validation in a larger cohort is warranted.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IDO1 (Indoleamine 2,3-dioxygenase 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • IDO1 expression
9ms
Epigenetically modified AP-2α by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression. (PubMed, Cell Death Dis)
5-Aza-dC (Decitabine) treatment combines with anti-PD-1 immunotherapy to efficiently suppress the progression of GL261 gliomas. Overall, these data support a mechanism of epigenetic modification of AP-2α that contributes to tumor immune evasion, and reactivation of AP-2α synergizes with anti-PD-1 antibodies to increase antitumor efficacy, which may be a broadly applicable strategy in solid tumors.
Journal • PD(L)-1 Biomarker • IO biomarker • Epigenetic controller
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • DNMT1 (DNA methyltransferase 1) • TFAP2A (Transcription Factor AP-2 Alpha)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression
|
decitabine
10ms
New P1 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Keytruda (pembrolizumab) • WM-A1-3389
10ms
Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. (PubMed, Ann Surg Oncol)
In summary, the integrated results show promising efficacy and safety of ICI-based neoadjuvant therapy for locally advanced gastric cancer and support further investigation in large multicenter randomized trials.
Retrospective data • Review • Journal • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
MSI-H/dMMR • PD-L1 underexpression • PD-L1-L
11ms
Elucidating the Role of PD-1/PD-L1 Axis in Solid Tumour CAR-T Cell Therapy (ASGCT 2023)
We are currently investigating the mechanisms behind these differences. Importantly, knocking out PD-1 was not detrimental in any of the CAR constructs used, even when their sensitivities to PD-1-PD-L1 inhibition diverged.
CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • MSLN (Mesothelin)
|
PD-L1 expression • HER-2 expression • PD-L1 underexpression • PD-L1 negative • IFNG expression • PD-L1-L